Pharma banks on EU court to highlight commercial risks of trial data disclosure
This article was originally published in SRA
Executive Summary
The commercial risks of a broad-brush full transparency policy by the European regulators are highlighted by three cases that have been filed in the European General Court against the European Medicines Agency by AbbVie and Intermune1-3.